Literature DB >> 25599464

Postoperative pro-adrenomedullin levels predict mortality in thoracic surgery patients: comparison with Acute Physiology and Chronic Health Evaluation IV Score*.

Abraham Schoe1, Emile F Schippers, Joachim Struck, Stefan Ebmeyer, Robert J M Klautz, Evert de Jonge, Jaap T van Dissel.   

Abstract

OBJECTIVES: Risk assessment in ICU patients using commonly used prognostic models may be influenced using different data definitions and by errors in data collection. We investigated whether a set of biomarkers (procalcitonin, MR-pro-adrenomedullin, CT-pro-endothelin-1, CT-pro-arginine vasopressin, and MR-pro-atrial natriuretic peptide), alone or as a panel, could be useful in postoperative risk assessment for hospital mortality in comparison with the Acute Physiology and Chronic Health Evaluation IV score.
DESIGN: In a prospective observational cohort study, we analyzed 800 consecutive patients undergoing elective cardiac surgery. We assessed biomarker levels on admission to the ICU and every 6 hours thereafter for 24 hours. For every postoperative time point and for every biomarker, we determined the predictive value for hospital mortality and made a comparison with the Acute Physiology and Chronic Health Evaluation IV score.
SETTING: Intensive care of an academic referral hospital. PATIENTS: A total of 800 consecutive patients undergoing elective cardiac surgery.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: MR-pro-adrenomedullin is a good predictor of mortality (c-statistic at time point 6 hr after admission to the ICU, 0.940; 95% CI, 0.918-0.956) and performed better than the Acute Physiology and Chronic Health Evaluation IV score (c-statistic, 0.842; 95% CI, 0.811-0.868). The c-statistic did not change significantly on the time points 6, 12, and 18 hours after admission. Using a cutoff value for proadrenomedullin taken 6 hours after admission on ICU (time point 2) of 3.2 nmol/L sensitivity was 81.8% and specificity 93.9%, the positive likelihood ratio was 13.3, positive predictive value was 31.0%, and negative predictive value was 99.4%. Patients with a MR-pro-adrenomedullin above this cutoff level had an odds ratio of 68.9 (95% CI, 22.2-213.1) for not surviving their hospital stay. The other biomarkers had less predictive power.
CONCLUSIONS: In elective cardiac surgery, MR-pro-adrenomedullin measured between 6 and 18 hours after admission to the ICU is a better predictor of hospital mortality in comparison with the Acute Physiology and Chronic Health Evaluation IV score.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25599464     DOI: 10.1097/CCM.0000000000000709

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  4 in total

1.  The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial.

Authors:  Gunnar Elke; Frank Bloos; Darius Cameron Wilson; Frank Martin Brunkhorst; Josef Briegel; Konrad Reinhart; Markus Loeffler; Stefan Kluge; Axel Nierhaus; Ulrich Jaschinski; Onnen Moerer; Andreas Weyland; Patrick Meybohm
Journal:  Crit Care       Date:  2018-03-21       Impact factor: 9.097

2.  Evaluation of the Postoperative Nursing Effect of Thoracic Surgery Assisted by Artificial Intelligence Robot.

Authors:  Xiufen Hu; Xiaodan He
Journal:  Contrast Media Mol Imaging       Date:  2021-11-16       Impact factor: 3.161

Review 3.  Beyond the Limits: Clinical Utility of Novel Cardiac Biomarkers.

Authors:  Radmilo Janković; Danica Marković; Nenad Savić; Vesna Dinić
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

4.  The usefulness of plasma levels of mature and total adrenomedullin as biomarkers indicating the magnitude of surgical stress responses: A single-center, prospective, observational study.

Authors:  Go Otao; Toyoaki Maruta; Tetsu Yonaha; Koji Igarashi; Sayaka Nagata; Kazuo Kitamura; Isao Tsuneyoshi
Journal:  J Clin Transl Res       Date:  2021-05-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.